SCHEMBL4157827

SCHEMBL4157827

NC(=O)Nc1cccc(C=C2c3ccccc3CCc3ccccc32)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.62
NR3C1 P04150 1/20 0.62
PGR P06401 1/20 0.62
NR3C2 P08235 1/20 0.62
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
MIF P14174 1/20 0.43
PSD A5PKW4 1/20 0.43
MAPK14 Q16539 5/20 0.41
HTR1A P08908 1/20 0.41
HTR7 P34969 1/20 0.41
DRD3 P35462 1/20 0.41
KMT2A Q03164 2/20 0.40
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4175603 0.87 NR3C1 (0.65) ARNR3C1PGRNR3C2NPC1
SCHEMBL4172303 0.85 NPC1 (0.54) ARNR3C1PGRNR3C2NPC1
SCHEMBL4163513 0.80 AR (0.52) ARNR3C1PGRNR3C2NPC1
SCHEMBL4157439 0.79 AR (0.69) ARNR3C1PGRNR3C2NPC1
SCHEMBL14092253 0.77 NR3C1 (0.54) ARNR3C1PGRNR3C2NPC1
SCHEMBL13802566 0.77 NR3C1 (0.51) ARNR3C1PGRNR3C2NPC1
SCHEMBL13802757 0.77 NR3C1 (0.50) ARNR3C1PGRNR3C2NPC1
SCHEMBL14092262 0.77 NR3C1 (0.50) ARNR3C1PGRNR3C2NPC1
SCHEMBL13802760 0.77 NR3C1 (0.50) ARNR3C1PGRNR3C2NPC1
SCHEMBL14092254 0.77 NR3C1 (0.53) ARNR3C1PGRNR3C2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS COGHLAN MICHAEL JOSEPH 2009-06-11 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-7411072-B2 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2008-08-12 US disclosed
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2006-03-23 US disclosed
WO-2004052847-A2 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149445-A1 TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS NR5A1, NR3C2, NR3C1 AR 48/4885NR3C1 3/4885PGR 54/4885
US-20060063759-A1 Tricyclic steroid hormone nuclear receptor modulators NR5A1, NR3C2, NR3C1 AR 45/4885NR3C1 3/4885PGR 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.